Diane Ling, MD

Assistant Professor of Clinical Radiation Oncology

Director of Quality and Safety for Keck Medicine

Image of Diane Ling, MD
Is this your profile? Click to edit

Overview

Dr. Diane C. Ling is an Assistant Professor of Clinical Radiation Oncology at the Keck School of Medicine. She joined the faculty in August, 2020. Her clinical practice is located at USC Norris Cancer Hospital.

She grew up in the Bay Area and Sacramento, and graduated from the University of California, Berkeley with a bachelor’s degree in Molecular and Cell Biology. She earned her medical doctorate degree at the University of Pittsburgh School of Medicine, where she was inducted into the Alpha Omega Alpha Honor Medical Society. She completed her residency at the University of Pittsburgh Medical Center, Hillman Cancer Center in Pittsburgh, PA, where she was chief resident.

Dr. Ling specializes in treating gastrointestinal and breast cancers. She has extensive experience with modern treatment techniques including intensity-modulated radiation therapy, volumetric-modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and motion management techniques. Her work has resulted in numerous publications, presentations at national meetings, and conference awards, including the Young Oncologist Essay Award as well as the James D. Cox Award of Scientific Merit from the American Radium Society.

Languages Spoken: English, Mandarin.

Publications

  • Hypofractionated Prostate Radiation Therapy: Adoption and Dosimetric Adherence Through Clinical Pathways in an Integrated Oncology Network. JCO Oncol Pract. 2021 04; 17(4):e537-e547.. View in PubMed
  • Ureteral stenosis after 3D MRI-based brachytherapy for cervical cancer – Have we identified all the risk factors? Radiother Oncol. 2021 02; 155:86-92. Rodríguez-López JL, Ling DC , Keller A, Kim H, Mo . View in PubMed
  • Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care? Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):390-393. Ling DC , Vargo JA, Beriwal S . . View in PubMed
  • Dose-escalated intensity modulated radiation therapy in patients with locally-advanced vulvar cancer – does it increase response rate? Gynecol Oncol. 2020 12; 159(3):657-662. Richman AH, Vargo JA, Lin . View in PubMed
  • Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? – A single-institution study. Gynecol Oncol. 2020 10; 159(1):23-29.. View in PubMed
  • Quality of Regional Nodal Irradiation Plans in Breast Cancer Patients Across a Large Network-Can We Translate Results From Randomized Trials Into the Clinic? Pract Radiat Oncol. 2021 Jan-Feb; 11(1):e3 . View in PubMed
  • Physician-Predicted Prognosis and Palliative Radiotherapy Treatment Utilization at the End of Life: An Audit of a Large Cancer Center Network. J Pain Symptom Manage. 2020 11; 60(5):898-905.e7.. View in PubMed
  • External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end-of-life. Cancer Med. 2020 08; 9(16):5781-5787.. View in PubMed
  • Dose-response model for severe late laryngeal toxicity after stereotactic body radiation therapy for previously-irradiated head and neck cancer. J Radiosurg SBRT. 2020; 7(2):89-94.. View in PubMed
  • Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status. Am J Clin Oncol. 2019 11; 42(11):837-844.. View in PubMed